Apogem Capital’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-39,741
Closed -$342K 80
2022
Q3
$342K Buy
39,741
+10,689
+37% +$106K 0.34% 93
2022
Q2
$237K Buy
29,052
+12,435
+75% +$119K 0.21% 128
2022
Q1
$202K Buy
+16,617
New +$350K 0.14% 153

Other funds holding NEO

Apogem Capital's NEO Position: Q4 2022 in Review

Apogem Capital sold out of NeoGenomics (NEO) in Q4 2022, closing a stake of 39,741 shares — an estimated $342K sold.

Apogem Capital first reported a position in NEO in Q1 2022 and held it in 3 quarters. The position peaked at $342K in Q3 2022. 244 funds tracked by Wall St. Rank hold NEO as of Q4 2022.

  • Apogem Capital reported no remaining NeoGenomics position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 39,741 NeoGenomics shares in Q4 2022, an estimated $342K.
  • Apogem Capital first reported a position in NeoGenomics in Q1 2022 and held it in 3 quarters.
  • Apogem Capital's NeoGenomics position peaked at $342K in Q3 2022.
  • 244 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.